Scholar Rock Holding Corporation (NASDAQ:SRRK) Eyes Repricing As FDA Review Nears Late-September
![]() |
Upcoming regulatory milestones concentrate near-term attention on the company while balance-sheet strength cushions operational runway. The combination of a resubmitted BLA and mixed technical momentum sets a catalyst-driven, range-bound near-term profile. |










